ACS Medicinal Chemistry Letters
Letter
(19) Secchiero, P.; Bosco, R.; Celeghini, C.; Zauli, G. Recent
advances in the therapeutic perspectives of Nutlin-3. Curr. Pharm. Des.
2011, 17, 569−577.
(20) Ding, Q.; Graves, B. J.; Kong, N.; Liu, J.-J.; Lovey, A. J.;
Pizzolato, G.; Roberts, J. L.; So, S.-S.; Vu, B. T.; Wovkulich, P. M.
4,4,5,5,-Tetrasubstituted Imidazolines. U.S. Patent 7,851,626, Decem-
ber, 14, 2010.
ACKNOWLEDGMENTS
■
We would like to thank Ted Lambros, Richard Szypula, and
Gino Sasso for analytical chemistry services, Christine Lukacs
and Ursula Kammlott for help in acquiring crystallographic
data, and Nader Fotouhi and John Roberts for simulating
discussions.
(21) Neef, G.; Eder, U.; Sauer, G. One-step conversions of esters to
2-imidazolines, benzimidazoles and benzothiazoles by aluminum
organic reagents. J. Org. Chem. 1981, 46, 2824−2826.
(22) Tovar, C.; Graves, B.; Packman, K.; Higgins, B.; Xia, M.;
Tardell, C.; Garrido, R.; Lee, E.; Kolinsky, K.; To, K.-H.; Linn, M.;
Podlaski, F.; Wovkulich, P.; Vu, B.; Vassilev, L. MDM2 small-molecule
antagonist RG7112 activates p53 signaling and regresses human
tumors in preclinical cancer models. Cancer Res. 2013, DOI: 10.1158/
0008-5472.CAN-12-2807.
(23) Tovar, C.; Rosinski, J.; Filipovic, Z.; Higgins, B.; Kolinsky, K.;
Hilton, H.; Zhao, X.; Vu, B. T.; Qing, W.; Packman, K.; Myklebost, O.;
Heimbrook, D. C.; Vassilev, L. T. Small-molecule MDM2 antagonists
reveal aberrant p53 signaling in cancer: implications for therapy. Proc.
Natl. Acad. Sci. U.S.A. 2006, 103, 1888−1893.
(24) Ray-Coquard, I.; Blay, J.-Y.; Italiano, A.; Le Cesne, A.; Penel, N.;
Zhi, J.; Heil, F.; Rueger, R.; Graves, B.; Ding, M.; Geho, D.; Middleton,
S. A.; Vassilev, L. T.; Nichols, G. L.; Bui, B. N. Effect of the MDM2
antagonist RG7112 on the p53 pathway in patients with MDM2-
amplified, well-differentiated or dedifferentiated liposarcoma: an
exploratory proof-of-mechanism study. Lancet Oncol. 2012, 13,
1133−1140.
REFERENCES
■
(1) Harris, S. L.; Levine, A. J. The p53 pathway: positive and negative
feedback loops. Oncogene 2005, 24, 2899−2908.
(2) Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network.
Nature 2000, 408, 307−310.
(3) Levine, A. J. p53, The cellular gatekeeper for growth and division.
Cell 1997, 88, 323−331.
(4) Hainaut, P.; Hollstein, M. p53 and human cancer: the first ten
thousand mutations. Adv. Cancer Res. 2000, 77, 81−137.
(5) Freedman, D. A.; Wu, L.; Levine, A. J. Functions of the MDM2
oncoprotein. Cell. Mol. Life Sci. 1999, 55, 96−107.
(6) Bond, G. L.; Hu, W.; Levine, A. J. MDM2 is a central node in the
p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 2005,
5, 3−8.
(7) Iwakuma, T.; Lozano, G. MDM2, an introduction. Mol. Cancer
Res. 2003, 1, 993−1000.
(8) Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine,
A. J. The mdm-2 oncogene product forms a complex with the p53
protein and inhibits p53-mediated transactivation. Cell 1992, 69,
1237−45.
(9) Kubbutat, M. H. G.; Jones, S. N.; Vousden, K. H. Regulation of
p53 stability by Mdm2. Nature 1997, 387, 299−303.
(10) Ashcroft, M.; Vousden, K. H. Regulation of p53 stability.
Oncogene 1999, 18, 7637−7643.
(25) Andreeff, M.; Kelly, K. R.; Yee, K.; Assouline, S.; Strair, R.;
Popplewell, L.; Bowen, D.; Martinelli, G.; Drummond, M. W.; Vyas,
P.; Kirschbaum, M.; Iyer, S. P.; Kojima, K.; Geho, D.; Blotner, S.;
Cheng, S.; Vassilev, L.; Ding, M.; Zhi, J.; Middleton, S.; Nichols, G.
Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2
Antagonist, in Acute Leukemia. Presented at the 54th Annual Meeting
of the American Society of Hematology, Georgia, Atlanta, December 8−
11, 2012; Abstract 675.
(11) Brown, C. J.; Lain, S.; Verma, C. S.; Fersht, A. R.; Lane, D. P.
Awakening guardian angels: Drugging the p53 pathway. Nat. Rev.
Cancer 2009, 9, 862−873.
(12) Vassilev, L. T. MDM2 inhibitors for cancer therapy. Trends Mol.
Med. 2007, 13, 23−31.
(13) Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.;
Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein
bound to the p53 tumor suppressor transactivation domain. Science
1996, 274, 948−953.
(14) Vu, B. T.; Vassilev, L. Small-molecule inhibitors of the p53-
MDM2 interaction. Curr. Top. Microbiol. Immunol. 2011, 348, 151−
172.
(15) Grasberger, B. L.; Lu, T.; Schubert, C.; Parks, D. J.; Carver, T.
E.; Koblish, H. K.; Cummings, M. D.; LaFrance, L. V.; Milkiewicz, K.
L.; Calvo, R. R.; Maguire, D.; Lattanze, J.; Franks, C. F.; Zhao, S.;
Ramachandren, K.; Bylebyl, G. R.; Zhang, M.; Manthey, C. L.; Petrella,
E. C.; Pantoliano, M. W.; Deckman, I. C.; Spurlino, J. C.; Maroney, A.
C.; Tomczuk, B. E.; Molloy, C. J.; Bone, R. F. Discovery and cocrystal
structure of benzodiazepinedione HDM2 antagonists that activate p53
in cells. J. Med. Chem. 2005, 48, 909−912.
(16) Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Wang, G.; Qiu, S.;
Shangary, S.; Gao, W.; Qin, D.; Stuckey, J.; Krajewski, K.; Roller, P. P.;
Wang, S. Structure-based design of spiro-oxindoles as potent, specific
small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem.
2006, 49, 3432−3435.
(17) Rew, Y.; Sun, D.; Gonzalez-Lopez De Turiso, F.; Bartberger, M.
D.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Deignan, J.; Fox, B.
M.; Gustin, D.; Huang, X.; Jiang, M.; Jiao, X.; Jin, L.; Kayser, F.;
Kopecky, D. J.; Li, Y.; Lo, M.-C.; Long, A. M.; Michelsen, K.; Oliner, J.
D.; Osgood, T.; Ragains, M.; Saiki, A. Y.; Schneider, S.; Toteva, M.;
Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Medina, J. C.;
Olson, S. H. Structure-based design of novel inhibitors of the MDM2−
p53 interaction. J. Med. Chem. 2012, 55, 4936−4954.
(18) Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.;
Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi,
N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule
antagonists of MDM2. Science 2004, 303, 844−848.
D
dx.doi.org/10.1021/ml4000657 | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX